The ID-Lyme project is all about making a novel test for the early detection of Lyme Borreliosis available to medical professionals and patients.
Lyme disease (Lyme Borreliosis, LB) is the well-known infectious disease caused by bacteria of the Borrelia type, which in turn are transmitted by ticks from the Ixodes genus. If untreated, the infection can cause many serious effects, including damage to joints, heart, and nervous system.
When applied in an early stage, a treatment with antibiotics is usually effective. Unfortunately, detection methods presently available are often unable to reliably diagnose the infection. Clearly, there is a need for a more sensitive and effective test that can detect the infection within weeks after the tick bite, before the onset of symptoms.
The ID-Lyme project aims specifically at developing such a test. The knowledge and expertise of the international project partners uniquely combine to make available the first point-of-care test for Borrelia infection in an early stage of the disease, thereby improving patient health outcomes, and reducing health cost from either unnecessary treatment or, worse, extensive treatment of advanced infection.
The project is supported by a EU grant under the Horizon 2020 research and innovation programme.
Cell-mediated immunity (CMI) tests are used to diagnose (prior) infection by intracellular pathogens. A logistical hurdle of CMI tests is the fact that living cells […]
€ 2 million for European Lyme Borreliosis innovation The European Union has granted almost € 2 million to an international consortium that will bring a […]